In particular, participants excluded from PSA testing—those with current prostate inflammation, recent prostate-related procedures, or a history of prostate cancer—often exhibit higher PSA levels and potentially more elevated inflammatory indicators (NMLR). The gene discussed is KLK3; the disease is urogenital neoplasm.